Article Listing - Profit up 22% at Gilead on pipeline strength

EC PHARMA MARKET FORECASTS TO 1996

27 April 1992

The European Community pharmaceutical market is expected to continue growing over the next five years at a rate in excess...

PROJECT REVIEW FROM NOVO NORDISK

27 April 1992

Highlighting its ongoing R&D in its recently released annual report for 1991, Denmark's Novo Nordisk notes that it intends to...

NEUTOGENA ACQUIRES INTEREST IN CELLEGY

27 April 1992

Neutrogena Corp has acquired a minority interest in Cellegy Pharmaceuticals, a dermatological products R&D company. Full terms of the agreement...

CIBA-GEIGY CONFIDENT IN FORTHCOMING RESULTS

27 April 1992

Ciba-Geigy chairman Alex Krauer has expressed confidence in the company's forthcoming 1992 results. He adds that the company is actively...

CAPOTEN CUTS MORTALITY IN SAVE

27 April 1992

Bristol-Myers Squibb's angiotensin converting enzyme inhibitor product Capoten (captopril) reduces mortality by 17% in post-myocardial infarct patients without overt heart...

FRENCH VOLUNTARY AIDS TESTING MEASURES

27 April 1992

The French government has adopted four measures to encourage voluntary AIDS testing and will boost the state AIDS prevention budget...

STOCK MARKET COMMENTARY: NEW YORK

27 April 1992

NEW YORK: experienced a triple-witching hour ahead of the Easter weekend, which pushed the Dow Jones to a new high,...

GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR

27 April 1992

Good sales growth was experienced by the major US pharmaceutical companies announcing results for the first quarter of 1992 in...

JAPAN'S PROJECTED 1992 MEDICAL COSTS

27 April 1992

An increase of 6.9% to 23,170 billion yen ($172.62 billion) is expected in Japan's medical costs for the current year,...

ROBERTS TO MARKET J&J'S SUPPRELIN

27 April 1992

Roberts Pharmaceutical has ob-tained exclusive worldwide rights to Johnson & Johnson's newly-approved orphan drug Supprelin (histrelin) for the treatment of...

Showing 94161-94170 of 95360 articles